MNMD

MNMD

USD

Mind Medicine (MindMed) Inc. Common Shares

$12.000-0.100 (-0.826%)

Reaalajas hind

Healthcare
Biotehnoloogia
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$12.100

Kõrge

$12.530

Madal

$11.880

Maht

2.12M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

1.2B

Tööstusharu

Biotehnoloogia

Riik

United States

Kauplemisstatistika

Keskmine maht

1.69M

Börs

NMS

Valuuta

USD

52 nädala vahemik

Madal $4.7Praegune $12.000Kõrge $14.43

Seotud uudised

BusinessWire

Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the closing

Vaata rohkem
Mind Medicine (MindMed) Inc. Announces Closing of Approximately $259 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
BusinessWire

Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing

Vaata rohkem
Mind Medicine (MindMed) Inc. Announces Pricing of $225 Million Public Offering
BusinessWire

MindMed Announces New Employee Inducement Grant

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance

Vaata rohkem
MindMed Announces New Employee Inducement Grant
Analyst Upgrades

Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position.

Vaata rohkem
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression